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The efficacy of ceftobiprole combined with vancomycin was tested against two vancomycin-intermediate
Staphylococcus aureus (VISA) strains, PC3 and Mu50, in rats with experimental endocarditis. Animals with
infected aortic vegetations were treated for 3 days with doses simulating the kinetics after intravenous
administration in humans of (i) the standard dose of ceftobiprole of 500 mg every 12 h (b.i.d.) (SD-cefto-
biprole), (ii) a low dose of ceftobiprole of 250 mg b.i.d. (LD-ceftobiprole), (iii) a very low dose of ceftobiprole
of 125 mg b.i.d. (VLD-ceftobiprole), (iv) SD-vancomycin of 1 g b.i.d., or (v) LD- or VLD-ceftobiprole combined
with SD-vancomycin. Low dosages of ceftobiprole were purposely used to highlight positive drug interactions.
Treatment with SD-ceftobiprole sterilized 12 of 14 (86%) and 10 of 13 (77%) vegetations infected with PC3 and
Mu50, respectively (P < 0.001 versus controls). In comparison, LD-ceftobiprole sterilized 10 of 11 (91%)
vegetations infected with PC3 (P < 0.01 versus controls) but only 3 of 12 (25%) vegetations infected with Mu50
(P > 0.05 versus controls). VLD-ceftobiprole and SD-vancomycin alone were ineffective against both strains
(<8% sterile vegetations). In contrast, the combination of VLD-ceftobiprole and SD-vancomycin sterilized 7 of
9 (78%) and 6 of 14 (43%) vegetations infected with PC3 and Mu50, respectively, and the combination of
LD-ceftobiprole and SD-vancomycin sterilized 5 of 6 (83%) vegetations infected with Mu50 (P < 0.05 versus
controls and monotherapy). Thus, ceftobiprole monotherapy simulating standard therapeutic doses was active
against VISA experimental endocarditis. Moreover, subtherapeutic LD- and VLD-ceftobiprole synergized with
ineffective vancomycin to restore efficacy. Hence, combining ceftobiprole with vancomycin broadens the ther-
apeutic margin of these two compounds against VISA infections.
Methicillin-resistant Staphylococcus aureus (MRSA) is a
leading cause of hospital- and community-acquired infections,
against which vancomycin is still considered the agent of
choice. However, continuous vancomycin selective pressure in
the clinical environment has led to the emergence of vanco-
mycin-intermediate S. aureus (VISA) strains, which have a
decreased susceptibility to glycopeptides.
Infections due to VISA are a concern because they are
associated with vancomycin therapeutic failure (27). More-
over, only a few treatment alternatives are currently available,
mainly daptomycin and linezolid. Daptomycin was approved
for the treatment of S. aureus bloodstream infections, including
right-sided endocarditis caused by methicillin-susceptible S.
aureus (MSSA) and MRSA (19, 38). However, in vitro studies
and case reports have suggested an association between de-
creased susceptibility to vancomycin and decreased suscepti-
bility to daptomycin (10, 34, 37), making the use of daptomycin
against VISA infections potentially problematic. Likewise, the
use of linezolid against S. aureus bacteremia has been disap-
pointing (8), and its use against infective endocarditis is pre-
cluded by the fact that it is not bactericidal (16).
An alternative to such limits is to identify synergistic com-
binations of existing compounds. For instance, vancomycin has
been often used in combination with rifampin or gentamicin to
treat infective endocarditis caused by MRSA (32). However,
the benefit of these combinations is debated (21). Moreover,
the risk of resistance to rifampin and gentamicin among
MRSA strains, together with the decreased susceptibility of
VISA to vancomycin, limits these therapeutic options. In ad-
dition, some investigators have reported synergism between
various -lactams and vancomycin against MRSA and VISA
isolates, both in vitro and in rabbits with experimental endo-
carditis (6, 13, 28, 36). However, other authors reported con-
tradictory observations in vitro, and some animal experiments
were unable to corroborate this synergism (1, 14, 21).
The aim of this study was to evaluate the potential synergis-
tic activity of ceftobiprole in combination with vancomycin
against two clinical isolates of VISA, both in vitro and in rats
with experimental endocarditis. Ceftobiprole is a novel broad-
spectrum cephalosporin with potent activity against Gram-pos-
itive pathogens, including MRSA and VISA (39), as well as
Gram-negative pathogens. It has been reported to be effica-
cious in monotherapy against experimental endocarditis
caused by both types of bacteria (4, 15, 45). It is therefore of
interest to evaluate ceftobiprole as a potential partner with
vancomycin for the treatment of endocarditis caused by MRSA
or VISA.
(This study was presented in part at the 20th ECCMID, 10
to 13 April 2010, Wien, Austria [abstr. O38], and at the 50th
ICAAC, 12 to 15 September 2010, Boston, MA [abstr. B062].)
MATERIALS AND METHODS
Bacterial strains and growth conditions. The well-described clinical VISA
isolates PC3 (42) and Mu50 (26) were used for in vitro and in vivo studies. MRSA
strain COL was included as a control strain for some in vitro experiments.
Bacteria were grown at 37°C in brain heart infusion (BHI) (Difco, Becton
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Dickinson, Sparks, MD). Strains were stored frozen in BHI containing 10%
(vol/vol) glycerol at 80°C and subcultured to ensure purity before testing.
Antimicrobials. Ceftobiprole (batch 08005R25C) and ceftobiprole medocaril
(the prodrug of ceftobiprole; batch 5003DR027) were supplied by Johnson and
Johnson (Raritan, NJ). Vancomycin was commercially purchased. All other
chemicals were reagent-grade commercially available products.
Susceptibility testing. MICs of ceftobiprole and vancomycin were determined
by broth macrodilution in accordance with the Clinical and Laboratory Standards
Institute (CLSI) guidelines (7). The MICs were the lowest concentration of
antibiotic that yielded no visible growth after 24 h of incubation at 37°C. A
minimum of two independent experiments were performed.
Drug interaction. Studies of interaction between ceftobiprole and vancomycin
were performed by Etest and population analysis. For Etest, a 0.5 McFarland
standard of each isolate was inoculated on plain BHI agar (BHIA) plates and on
BHIA plates containing 0.5 times the MIC of ceftobiprole (1 g/ml for PC3 and
0.5 g/ml for Mu50) or 0.5 times the MIC of vancomycin (4 g/ml for both PC3
and Mu50). Etest strips of ceftobiprole (Johnson and Johnson, Raritan, NJ) and
Etest strips of vancomycin (AB Biodisk, Solna, Sweden) were then placed on
plain BHIA plates and on vancomycin- or ceftobiprole-containing agar plates,
respectively. The plates were then incubated for 24 h at 37°C. Positive interaction
was defined as an enhancement in the zone of inhibition surrounding the Etest
strip on BHIA plates containing vancomycin or ceftobiprole compared to the
zone size around Etest strips placed on BHIA plates containing no antibiotic.
For population analysis, series of bacterial inocula (between 102 and 109 CFU)
of the test strains were serially diluted and spread onto BHIA plates supple-
mented with increasing concentrations of ceftobiprole or vancomycin alone or
with the partner drug incorporated in the agar at a fixed concentration of 0.5
times the MIC for each organism. The plates were then incubated for 48 h at
37°C before the colonies were enumerated. The population curve was drawn by
calculating and plotting the number of cells giving rise to colonies against the
concentration of the drug.
Time-kill studies. Drug-induced killing and bactericidal synergy between
ceftobiprole and vancomycin were assessed by time-kill studies. Experiments
were performed in flasks containing 10 ml of prewarmed Mueller-Hinton broth
(MHB) (Becton Dickinson) without antibiotic or supplemented with cefto-
biprole or vancomycin alone at 0.5 and 1 times the MIC for each organism or
with the combination of both antibiotics. Flasks were inoculated with the test
strains at a final concentration of 106 CFU/ml. A 100-l aliquot was removed
from the flask at 0, 4, and 24 h, serially diluted in saline, and plated on antibiotic-
free agar plates to determine colony counts. The dilution method avoided po-
tential carryover of the drugs. The lower limit of detection was 1 log10 CFU/ml.
All experiments were repeated on two or three independent occasions.
Bactericidal activity was defined as a3-log10 decrease in colony counts below
the starting inoculum after 24 h of exposure to the drugs. Synergism was defined
as a 2 log10 increased killing at 24 h by the drug combination over that of the
more active drug tested alone and as a 2 log10 decrease in colony count below
the starting inoculum. Indifference was defined as a2 log10 change (increase or
decrease) in colony counts with the combination in comparison with that with the
most active single antimicrobial alone. Antagonism was defined as a 2 log10
increase in colony counts afforded by the drug combination compared to the
most active drug used alone.
PBP analysis. Penicillin binding proteins (PBPs) were determined in mem-
brane fractions of bacterial lysates as described previously (20). Membranes
containing PBPs were first incubated (20 min at 37°C) with either ceftobiprole (1
times the MIC) or vancomycin (0.5 times the MIC) alone or with ceftobiprole (1
times the MIC) plus vancomycin (0.5 times the MIC) and then were labeled with
1 g/ml Bocillin FL (Invitrogen, Carlsbad, CA) for 1 h at 37°C as previously
described (24, 47). After incubation, the proteins were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis using a NuPAGE 7% Tris-
acetate precast gel (Invitrogen). The Bocillin FL-labeled PBPs were visualized by
direct scanning of the gels with a Typhoon Trio imager (Amersham Biosci-
ences). Intensities of the bands were quantified by densitometry using ImageJ
software (Wayne Rasband, National Institutes of Health, Bethesda, MD).
Cell wall preparation and muropeptide analysis. Cell walls were purified from
bacteria collected in the exponential growth phase (optical density at 600 nm
[OD600] of 0.6) as previously described (31). Briefly, organisms were grown in
BHI broth supplemented or not with 0.5 times the MIC of ceftobiprole or
vancomycin alone or together. Subinhibitory concentrations were used in order
to allow bacterial growth. The peptidoglycan was purified and digested with
mutanolysin (Sigma, Buchs, Switzerland), and the muropeptides were separated
by reverse-phase high-performance liquid chromatography (HPLC) as described
by de Jonge et al. (12). The degree of muropeptide cross-linking was calculated
by quantification of the relative amounts of monomers, dimers, trimers, and
oligomers in the muropeptide digest as described by Snowden and Perkins (44).
Experimental endocarditis. Animal experiments were carried out in accor-
dance with Swiss legislation. The production of catheter-induced aortic vegeta-
tions and the installation of the infusion pump device to deliver the antibiotics
were performed in female Wistar rats (Charles River Laboratories, L’Arbresle,
France) as described previously (18, 25). The administration of drug combina-
tions necessitated the use of two infusion pumps (one for each drug) (46). Valve
infections were induced 24 h after catheterization by intravenous (i.v.) challenge
of the animals with 0.5 ml of saline containing 106 CFU of the test organisms
(strains PC3 or Mu50). This inoculum consistently ensured endocarditis in 100%
of the control animals as determined in pilot studies.
Antibiotics were delivered at changing flow rates, via the infusion pump, at
doses that simulated in rats the drug kinetics in sera of humans during treatment
with (i) the standard dose of ceftobiprole of 500 mg given i.v. every 12 h (b.i.d.)
(SD-ceftobiprole) (40), (ii) a low dose of ceftobiprole of 250 mg i.v. every 12 h
(LD-ceftobiprole) (41); (iii) a very low dose of ceftobiprole of 125 mg i.v. every
12 h (VLD-ceftobiprole) (40), (iv) SD-vancomycin of 1 g i.v. every 12 h (2), or (v)
the combination of LD-ceftobiprole or VLD-ceftobiprole with SD-vancomycin.
This required total drug amounts (per kilogram of body weight over a period of
12 h) of 17.2 mg ceftobiprole medocaril for SD-ceftobiprole, 5.88 mg for LD-
ceftobiprole, and 1.22 mg for VLD-ceftobiprole and 23.2 mg of SD-vancomycin.
SD-ceftobiprole was used to test the efficacy of the recommended dosage in
humans. LD-ceftobiprole and VLD-ceftobiprole were subtherapeutic regimens
purposely chosen to detect possible synergies with vancomycin. Each experiment
included a control group of untreated animals.
Therapy was started at 12 h after bacterial challenge and lasted for 3 days.
Control rats were killed at the onset of treatment in order to determine both the
frequency and the severity of infection at the start of therapy, and treated rats
were killed 8 h after the end of the last antibiotic dose. Aortic vegetations and
spleens were removed, weighed, homogenized in 1 and 2 ml of saline, respec-
tively, and serially diluted before being plated on BHI agar plates for determi-
nation of colony counts. This process reduced the potential antibiotic carryover.
Quantitative blood cultures were performed in parallel. Plates were incubated
for 48 h at 37°C to determine the number of viable organisms remaining in the
vegetations. The lower limits of detection of growth were 2 log10 CFU/g of
vegetation and 1 log10 CFU/g of spleen.
In order to detect in vivo selection of ceftobiprole- or vancomycin-resistant
subpopulations during therapy, 0.1-ml samples from each vegetation homoge-
nate were plated directly onto BHI agar plates supplemented with increasing
concentrations of ceftobiprole or vancomycin as in the population analysis pro-
files. Viable counts were plotted against the ceftobiprole or vancomycin concen-
tration and compared with the profiles of bacteria from vegetations of control
animals.
Pharmacokinetic studies. When used alone, the concentrations of ceftobiprole
and vancomycin in the serum of rats were determined by an agar diffusion assay
with antibiotic medium 1 (Difco) and Bacillus subtilis ATCC 6633 as the indica-
tor organism. Standard curves were determined using pooled rat serum. The
limits of detection of the assays were 0.25 g/ml for ceftobiprole and 0.7 g/ml
for vancomycin. The linearities of the standard curves were assessed with a
regression coefficient of0.995 for both ceftobiprole and vancomycin. Intraplate
and interplate variations were 10%. When administered in combination, cefto-
biprole was determined by an agar diffusion assay with antibiotic medium 1
(Difco) and Escherichia coli ATCC 25922 (which is resistant to vancomycin) as
the indicator organism, and vancomycin was measured by fluorescent polariza-
tion immunoassay. The detection limits in these assays were 0.5 g/ml for
ceftobiprole and 0.75 g/ml for vancomycin.
Statistical analysis. The degrees of muropeptide cross-linking of pepti-
doglycan purified from bacteria exposed to various drugs or drug combina-
tions were compared by analysis of variance (ANOVA) with Bonferroni’s
correction for multiple-comparison tests. The rates of valve, spleen, and
blood infections of the various groups and the differences in mortality were
compared by Fisher’s exact test. Median bacterial counts in vegetations in the
control and SD-ceftobiprole groups were compared by the Mann-Whitney
rank sum test. The SD-ceftobiprole 500-mg monotherapy arm was not used as
a comparator with the other monotherapy or bitherapy groups, since it was
not tested in combination studies. Median bacterial counts in vegetations in
the control and the other groups were compared by the Kruskal-Wallis test
with Dunn’s correction for multiple-comparison groups. For statistical com-
parisons, culture-negative vegetations and spleens were considered to contain
2 and 1 log10 CFU/g, respectively, the limits of detection. A P value of 0.05
was considered significant.
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RESULTS
MICs, drug interaction, and time-kill experiments. The
MICs of ceftobiprole and vancomycin were 2 and 8 g/ml for
VISA PC3 and 1 and 8 g/ml for VISA Mu50, respectively.
The MICs of ceftobiprole and vancomycin for MRSA COL
were 1 and 2 g/ml, respectively.
Figures 1 and 2 present the interaction of ceftobiprole with
vancomycin for the two VISA strains tested. Combinations of
ceftobiprole and vancomycin demonstrated a positive interac-
tion against both strains PC3 and Mu50. Indeed, by Etest, an
enhanced zone of inhibition surrounding the ceftobiprole Etest
strip was observed in the presence of vancomycin (at a con-
centration of 0.5 times the MIC), which corresponded to in-
creases of 8-fold and 2-fold in the ceftobiprole susceptibilities
of PC3 and Mu50, respectively (Fig. 1A and C). The positive
interaction also operated in the symmetric setting, i.e., an en-
hanced zone of inhibition surrounding the vancomycin Etest
strip was observed when plating was on 0.5 times the MIC of
ceftobiprole (Fig. 1B and D). This corresponded to increases
in vancomycin susceptibility of 8-fold and 4-fold for strains
PC3 and Mu50, respectively. For MRSA COL, the suscepti-
bilities to ceftobiprole and vancomycin in the presence of the
partner drug, at a fixed concentration of 0.5 times the MIC,
increased by 4-fold and 2-fold, respectively (data not shown).
The positive interaction between ceftobiprole and vancomy-
cin could also be demonstrated by population analysis (Fig. 2).
When ceftobiprole was combined with vancomycin incorpo-
rated in the agar at a fixed concentration of 0.5 times the MIC,
the growth of the less susceptible subpopulation was pre-
vented, as indicated by a shift to the left of the population
analysis curve. Moreover, when vancomycin was combined
with ceftobiprole incorporated in the agar at a fixed concen-
tration of 0.5 times the MIC, a virtual disappearance of van-
FIG. 1. Positive interaction between ceftobiprole (BPR) and van-
comycin (VAN) by Etest testing. A 0.5 McFarland standard of VISA
PC3 (A and B) or VISA Mu50 (C and D) was inoculated on plain BHI
agar plates (BHIA) and on BHIA plates containing 0.5 times the MIC
of vancomycin (A and C) or 0.5 times the MIC of ceftobiprole (B and
D). Etest strips of ceftobiprole (A and C) or vancomycin (B and D)
were then placed on the plates, and the plates were incubated at 37°C
for 24 h. A marked increase in zone size around Etest ceftobiprole and
vancomycin strips was observed in the presence of the partner drug
incorporated in the agar.
FIG. 2. Population analysis of strains VISA PC3 and VISA Mu50. Large inocula (ca. 109 CFU) of the tests strains were spread onto BHI agar
plates supplemented with increasing concentrations of ceftobiprole alone (A) or vancomycin alone (C) or combined with vancomycin (B) or
ceftobiprole (D) incorporated in the agar at a fixed concentration of 0.5 times the MIC for each organism. The plates were incubated at 37°C for
48 h before the colonies were enumerated.
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comycin-resistant subpopulations was observed, and the two
VISA isolates displayed a profile close to that of the vancomy-
cin-susceptible MRSA COL strain.
To test whether this positive interaction translated into bac-
tericidal synergy, time-kill assays were performed using cefto-
biprole and vancomycin concentrations of 0.5 and 1 times the
MIC. The rates of in vitro killing are presented in Fig. 3. At
these low concentrations, ceftobiprole or vancomycin alone did
not display significant bactericidal effects (i.e., 1.5 log kill at
any time point). In contrast, the combination of ceftobiprole at
1 times the MIC plus vancomycin at 0.5 times the MIC was
synergistic against both PC3 and Mu50, as demonstrated by
killing at 24 h of 3 and 2.5 log10 CFU/ml, respectively,
compared with single agents used alone and the initial inocu-
lum (Fig. 3A and B). The combination of ceftobiprole at 0.5
times the MIC and vancomycin at 1 times the MIC was posi-
tive, yet formally indifferent, against PC3 (loss of 2 log10
CFU/ml at 24 h for the combination compared with vancomy-
cin and the initial inoculum) and was synergistic against Mu50,
with a loss of viability of 2.6 log10 CFU/ml at 24 h for the
combination compared with each single agent and the initial
inoculum (Fig. 3C and D). The combination of ceftobiprole
and vancomycin at concentrations of 0.5 times the MIC for
each strain was indifferent against both isolates (data not pre-
sented).
PBP analysis. Figure 4 depicts PBP labeling with Bocillin FL
after preincubation of plasma membranes of strains PC3 and
Mu50 with or without the tested drugs. In the absence of drug
preincubation, PBPs 1, 2a, 2, and 3 were readily detected, while
PBP 4 was poorly labeled (Fig. 4, lanes A and E). Preincuba-
tion with 1 times the MIC of ceftobiprole saturated the “nor-
mal” PBPs, and decreased PBP2a labeling by approximately
4-fold for PC3 and 2-fold for Mu50 (Fig. 4, lanes B and F). In
contrast, no changes in Bocillin FL labeling were observed in
membranes preincubated with 0.5 times the MIC of vancomy-
cin (Fig. 4, lanes C and G), and vancomycin did not signifi-
cantly modify the ability of ceftobiprole to block the PBP
labeling when both drugs were used in combination (Fig. 4,
lanes D and H).
Muropeptide analysis. Figure 5 shows the muropeptide fin-
gerprints generated by muramidase digestion of peptidoglycan
purified from isolates PC3 and Mu50 grown in the absence or
the presence of subinhibitory concentrations of ceftobiprole or
vancomycin alone or with the combination of the two drugs.
The degrees of cross-linking for PC3 and Mu50 (73% and
57%, respectively) decreased by ca. 10% following exposure to
vancomycin, as judged by a decrease in the proportion of the
oligomer peaks and an increase in the proportion of monomer
peaks. After exposure to ceftobiprole alone, the HPLC profiles
of both PC3 and Mu50 showed a significant reduction (to 52%
and 46%, respectively) of the amount of cross-linking (P 
FIG. 3. Time-kill curves for VISA PC3 (left panel) and VISA Mu50 (right panel) after incubation with ceftobiprole (BPR) or vancomycin
(VAN) at concentrations of 0.5 and 1 times the MIC alone or in combination.
FIG. 4. PBP patterns of VISA strains PC3 and Mu50. Membrane
preparations were incubated with no antibiotic (lanes A and E), cefto-
biprole at 1 times the MIC alone (lanes B and F), vancomycin at 0.5
times the MIC alone (lanes C and G), or the combination of cefto-
biprole and vancomycin (lanes D and H) and labeled with Bocillin FL.
The samples were resolved by SDS-polyacrylamide gel electrophoresis,
and the Bocillin FL-labeled PBPs were visualized by scanning of the
gels using a Typhoon Trio imager. Numbers at right are molecular
masses in kilodaltons.
3980 ENTENZA ET AL. ANTIMICROB. AGENTS CHEMOTHER.
0.005). After exposure to the combination of ceftobiprole and
vancomycin, cell wall cross-linking was not further reduced and
was 55% and 43% for PC3 and Mu50, respectively.
Pharmacokinetic studies. The peak (30-min) and trough
(12-h) concentrations (mean  standard deviation for 3 to
12 individual animals) of simulated human doses of cefto-
biprole in rat serum were, respectively, 45.1  9.5 g/ml and
3.9  0.9 g/ml for SD-ceftobiprole (500 mg), 19.4  4.4
g/ml and 0.8  0.2 g/ml for LD-ceftobiprole (250 mg),
and 11.3  2.9 g/ml and 0.6  0.2 g/ml for VLD-cefto-
biprole (125 mg). The peak and trough concentrations
(mean  standard deviation for 3 individual animals) of
vancomycin were 58.9  6.9 g/ml and 6.8  0.6 g/ml,
respectively. These values for ceftobiprole and vancomycin
in rats were very close to the peak and trough values re-
ported in humans, i.e., 40.6 and 1.3 g/ml for SD-cefto-
biprole (500 mg), 19.5 and 0.8 g/ml for LD-ceftobiprole
(250 mg), and 52.5 and 5.2 g/ml for vancomycin, respec-
tively (2, 40, 41). No reduction in ceftobiprole and vanco-
mycin levels in serum with the combination of the two drugs
was observed.
Therapy of experimental endocarditis. The results for ther-
apy of experimental endocarditis are shown in Table 1. Treat-
ment with SD-ceftobiprole simulating human kinetics of 500
mg b.i.d. sterilized 93% and 77% of vegetations infected with
strains PC3 and Mu50, respectively, and reduced the vegeta-
tion counts by6 log10 CFU/g compared to those in untreated
controls (P  0.001). The high efficacy of the SD-ceftobiprole
(500-mg) regimen did not allow us to study its potential syn-
ergism with vancomycin. Thus, further treatments used lower
doses of the drug.
Treatment with doses simulating human pharmacokinetics
of LD-ceftobiprole (250 mg) sterilized 91% of animals inocu-
lated with PC3 and reduced the vegetation counts by 6 log10
CFU/g compared to those in untreated controls (P  0.001).
However, this regimen was ineffective against Mu50 (only 25%
of valves were sterile). Both VLD-ceftobiprole (125 mg) and
SD-vancomycin failed to cure the animals. In sharp contrast,
FIG. 5. HPLC elution profiles of muropeptides isolated from VISA strains PC3 and Mu50. Peptidoglycan was purified from bacteria grown in
the absence or presence of subinhibitory concentrations of ceftobiprole (BPR) or vancomycin (VAN) alone or with the combination of the two
drugs and digested with muramidase, and the muropeptides were separated by HPLC. Peaks 5, 11, 15, 16, and 17 represent the monomeric
muropeptides. The HPLC profile eluting with retention times of greater than 100 min (i.e., after peak 17) represents highly cross-linked oligomeric
components.
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the combination of LD-ceftobiprole with SD-vancomycin suc-
cessfully treated 83% of vegetations infected with Mu50, and
VLD-ceftobiprole plus SD-vancomycin was successful against
both PC3 and Mu50 (78% and 43% culture-negative vegeta-
tions, respectively; P  0.05 compared to controls and either
drug given alone). No ceftobiprole- or vancomycin-resistant
subpopulations were detected in vegetation homogenates of
treated animals during the study period.
Table 1 also shows the results for spleen tissue cultures. In
general, spleens remain infected even after effective antibiotic
therapy of the valves, although with decreased bacterial num-
bers. Treatment with SD-ceftobiprole significantly decreased
bacterial densities in the spleens infected with both test isolates
(P  0.001 compared to controls). Likewise, all combination
regimens significantly (P  0.05) decreased median bacterial
densities in the spleens relative to both untreated controls and
monotherapy. On the other hand, monotherapy with LD-cefto-
biprole, VLD-ceftobiprole, and SD-vancomycin was ineffec-
tive, with the exception of LD-ceftobiprole against VISA PC3.
None of the control animals at the start of therapy had
sterile blood cultures. Available animals were also analyzed for
positive blood cultures at the end of treatment. Blood cultures
were sterile in 93 to 100% of animals treated with SD-cefto-
biprole (P  0.001 versus untreated controls), 78 to 100% of
animals treated with LD-ceftobiprole (P  0.01 versus un-
treated controls), 20 to 33% of animals treated with VLD-
ceftobiprole (P  0.05 versus untreated controls), and 0 to
25% of animals treated with SD-vancomycin (P  0.05 versus
untreated controls). LD-ceftobiprole plus SD-vancomycin ster-
ilized 100% of blood cultures in rats challenged with Mu50
(P  0.0001 versus controls and monotherapy), and VLD-cefto-
biprole plus SD-vancomycin sterilized 80 to 100% of blood cul-
tures (P  0.05 versus controls and single drug therapy).
DISCUSSION
New -lactams exhibiting good anti-MRSA activity have an
improved affinity for PBP 2a (3, 23, 33). This makes them
active against MRSA, VISA, and even high-level-vancomycin-
resistant S. aureus (VRSA). Anti-MRSA activity is mediated
by the ability to inhibit both normal PBPs and PBP 2a, and
anti-VISA and anti-VRSA activities take advantage of the fact
that -lactams act via antibacterial mechanisms that are dif-
ferent from that of vancomycin. However, while blocking PBP
2a may overcome resistance in MRSA, VISA, and VRSA, it
may be risky to limit the antimicrobial strategy to this unique
approach. Indeed, one could underestimate the ability of the
bacterium to develop further resistance to the new -lactams,
for instance, by introducing new mutations in the regulatory or
structural genes of PBP 2a (30). This risk needs to be pre-
vented.
One strategy for resistance prevention could be combining
-lactams with vancomycin. Indeed, while VISA strains are
resistant to most -lactams and vancomycin, it was recently
observed that combining both types of drugs together restored
their activity against these organisms in vitro and partially in
vivo (6, 14). Thus, when -lactams (e.g., nafcillin) and vanco-
mycin were applied together against VISA, the mechanisms of
resistance to these two drugs became mutually exclusive.
Here we investigated the potential benefit of such a strategy
by combining ceftobiprole with vancomycin against VISA PC3
and VISA Mu50 clinical isolates. Of note, ceftobiprole mono-
therapy was active when administered to animals at doses
mimicking the treatment recommended in human (i.e., 500 mg
b.i.d.), thus confirming its intrinsic activity against VISA (4, 15,
45). On the other hand, it was not effective when used at low
or very low doses, but these subtherapeutic doses could be
TABLE 1. Treatment of experimental endocarditis induced by VISA strains PC3 and Mu50
VISA strain and treatment groupa
No. of sterile
samples/total no. (%) in: Median (range) log10 CFU/g in:
Vegetation Spleen Vegetation Spleen
PC3
Control 0/14 (0) 0/14 (0) 8.46 (5.06–9.42) 4.70 (4.11–5.76)
SD-ceftobiprole 500 13/14 (93)b 1/14 (7) 2.00 (2.00–3.20)b 2.21 (1.00–2.97)b
SD-vancomycin 0/7 (0) 0/7 (0) 7.38 (5.99–9.56) 5.59 (4.87–6.67)
LD-ceftobiprole 250 10/11 (91)c 0/11 (0) 2.00 (2.00–4.38)c 2.99 (1.57–4.11)c
VLD-ceftobiprole 125 1/12 (8) 0/12 (0) 8.09 (2.00–9.42) 4.72 (2.28–6.69)
LD-ceftobiprole 250  SD-vancomycin NDe ND ND ND
VLD-ceftobiprole 125  SD-vancomycin 7/9 (78)d 0/9 (0) 2.00 (2.00–8.06)d 2.87 (2.30–3.14)d
Mu50
Control 0/14 (0) 0/14 (0) 8.23 (7.02–9.16) 4.71 (3.96–5.68)
SD-ceftobiprole 500 10/13 (77)b 5/13 (38)b 2.00 (2.00–3.86)b 2.33 (1.00–3.61)b
SD-vancomycin 0/8 (0) 0/8 (0) 9.03 (5.56–9.34) 4.96 (3.94–6.41)
LD-ceftobiprole 250 3/12 (25) 3/12 (25) 5.31 (2.00–9.27)c 3.99 (1.00–5.56)
VLD-ceftobiprole 125 0/15 (0) 0/15 (0) 8.87 (5.71–9.38) 5.42 (4.38–6.72)
LD-ceftobiprole 250  SD-vancomycin 5/6 (83)d 1/6 (17) 2.00 (2.00–4.78)d 1.95 (1.00–3.04)d
VLD-ceftobiprole 125  SD-vancomycin 6/14 (43)d 4/14 (28) 5.09 (2.00–8.07)d 2.50 (1.00–5.64)d
a SD-ceftobiprole 500, LD-ceftobiprole 250, and VLD-ceftobiprole 125, simulation in rats of human pharmacokinetics following 500, 250, and 125 mg i.v. every 12 h,
respectively. SD-vancomycin, simulation of 1 g i.v. every 12 h.
b P  0.001 versus controls.
c P  0.01 versus controls and vancomycin.
d P  0.05 versus controls and single-drug therapy alone.
e ND, not done.
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remediated by combination with vancomycin at an inactive
dose. This synergism was also apparent in population analysis
profiles in vitro, where low doses of one drug could prevent the
growth of subpopulations resistant to the partner drugs, and by
the fact that low-dose drug combinations prevented the emer-
gence of resistant escape mutants during therapy in vivo.
Synergy between subtherapeutic doses of ceftobiprole and
vancomycin against MRSA was also suggested in a recent
meeting abstract (17). Nevertheless, the exact mechanism of
this synergism is as yet incompletely elucidated. It was pro-
posed that alterations in the cell wall that confer vancomycin
resistance made these isolates simultaneously more susceptible
to -lactams (43). Alternatively, Howe et al. suggested that
high concentrations of -lactams may cause inhibition of syn-
thesis of proteins essential for the expression of vancomycin
resistance, thus resulting in synergy (28). Eventually, the mu-
tual exclusion of both resistance mechanisms could also result
from complementary interactions of the drugs with peptidogly-
can assembly. The logic of this argument is as follows: (i) the
VISA phenotype is associated with a thickened peptidoglycan
carrying an increased proportion of free D-alanine–D-alanine
termini, which trap incoming vancomycin; (ii) the free D-ala-
nine–D-alanine is synonymous with decreased PBP-mediated
transpeptidation, resulting in a less cross-linked and (probably)
mechanically weaker peptidoglycan; and (iii) additional weak-
ening of peptidoglycan by blockage of remaining PBPs with
-lactams further decreases peptidoglycan stability and results
in cell death. In this model it is critical that the -lactams block
all of the essential staphylococcal PBPs for the synergism to
occur. Thus, -lactams with increased PBP 2a affinity are likely
to be more efficient than -lactams with affinity restricted to
the “normal” staphylococcal PBPs in the combination with
vancomycin.
Here we had a glimpse of ceftobiprole and vancomycin
blockage of PBP labeling by Bocillin FL and of the effects of
these drugs on muropeptide cross-linkage as analyzed by
HPLC. Ceftobiprole readily blocked PBP labeling, including
labeling of PBP 2a (11). In contrast, vancomycin had no effect
on PBP labeling when used either alone or in combination with
ceftobiprole. Although this last result was expected, it excluded
any unforeseen interaction between ceftobiprole (which mim-
ics D-alanine–D-alanine) and vancomycin, which could inter-
fere with PBP blockage. Another hypothesis, alluded to above,
is that both drugs could synergize to decrease D-alanine–
D-alanine cross-linkage. However, peptidoglycan analyses
showed that while sub-MIC concentrations of ceftobiprole sig-
nificantly decreased cross-linkage (by increasing the ratio of
monomers), sub-MIC concentrations of vancomycin did not,
and combining both drugs was not more effective than using
ceftobiprole alone in this regard. Therefore, one is left with
another possibility, that the mutual benefit of both drugs would
result from the summation of transpeptidase inhibition, by
ceftobiprole, and transglycosidase inhibition, by vancomycin.
This is reminiscent of the synergism between PBP 2a blockage
and moenomycin, which specifically blocks transglycosidase
(35). Although not formally tested here (which would require
measurement of the length of the glycan chains in addition to
the transpeptidation activity), this is logical and should be used
as a further working hypothesis.
The present observations may also help clarify some contra-
dictory results previously reported with -lactam–vancomycin
combinations against MRSA and VISA. For instance, Climo et
al. (6) and Rochon-Edouard et al. (36) reported a synergistic in
vitro effect of combinations of different -lactam antibiotics
and vancomycin against clinical MRSA and VISA isolates. In
addition, Climo et al. (6) have shown that the combination of
nafcillin and vancomycin significantly reduced vegetation col-
ony counts in experimental endocarditis caused by VISA
strains compared to either treatment alone. On the other hand,
some studies have reported indifference or antagonism of
some -lactam–vancomycin combinations in vitro (1, 22, 28),
and synergism could not be demonstrated with oxacillin and
vancomycin in a mouse peritonitis model (14).The discrepancy
regarding the effects of -lactam–vancomycin combinations
against MRSA and/or VISA could be related to the binding
affinities of -lactams for PBPs, including PBP 2a, the major
determinant for methicillin resistance in MRSA and VISA.
For instance, synergism was stronger when -lactams with rel-
atively high PBP 2a affinities, i.e., amoxicillin-clavulanate, am-
picillin-sulbactam, or nafcillin (5, 20), were used as partner
drugs (6, 36). The present study with ceftobiprole extends
these observations and suggests that blocking PBP 2a in addi-
tion to the normal PBPs might be necessary for optimal syn-
ergy.
Moreover, the utilization of strains expressing different het-
erogeneous resistance phenotypes toward -lactams could also
account for some discordant results. The fact that in the pres-
ent study ceftobiprole given alone at subtherapeutic doses
(with human-like pharmacokinetics of 250 mg i.v. every 12 h)
was effective against VISA PC3 but not against VISA Mu50
supports this hypothesis. Indeed, the PC3 isolate presents a
highly heterogeneous phenotype toward oxacillin (inhibited by
1 g/ml) (42) and displayed more ceftobiprole-susceptible
subpopulations than the Mu50 strain.
In conclusion, the combination of ceftobiprole and vanco-
mycin was synergistic against VISA in vitro and in rats with
endocarditis. These results, as well as those observed against
MRSA in similar experiments (17), suggested that this combi-
nation therapy might be useful for the treatment of multire-
sistant S. aureus infections in humans. In particular, it increases
the margin of treatment efficacy, and consequently the efficacy
and safety in severe infections such as infective endocarditis,
where drug penetration at the infection site might be impaired
(9). Further studies examining the potential role of this com-
bination are warranted. Whether or not other novel cephalo-
sporins with activity against MRSA and VISA, i.e., ceftaroline
(29), would have the same synergistic properties in combina-
tion with vancomycin remains to be evaluated.
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